Equillium
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2223 Avenida De La Playa Ste 105, La Jol...Phone Number
(858) 240-1200Website
www.equilliumbio.comRevenue
<$5 MillionStock Symbol
EQIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Equillium
Equillium, Inc a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.Explore more
Equillium Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Equillium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Equillium
Earning: See what the market has to say on Equillium recently announced quarterly report
Click to see if Equillium had a recent Job posting/layoffs
Equillium, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Equillium launches new products
Check out if Equillium is spiking on competitors!
Check if Equillium has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Equillium has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Equillium
Compare insights from companies similar to Equillium, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Equillium is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Equillium is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Equillium.
Equillium financials insights
Gather financial insights about Equillium, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$15M
2025
Stock/Share Issuance
$50M
2026
Stock/Share Issuance
$35M
Equillium Tech Stack
A closer look at the technologies used by Equillium
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Person-Based
Business Finance, Finance, Financial Strategy
Person-Based
Business Finance, Finance, Financing & Debt
Funding
Funding
Person-Based
Clinical Operations, Finance, Financial Operations
Equillium News & Media
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
LA JOLLA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55pm EDT.Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ETEquillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafterEquillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on May 1, 2026, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 800,000 shares of common stock to two new employees under Equillium’s 2024 Inducement Plan. The Compensation Committee
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Equillium
Sign Up For FreeTo access detailed company insights
Equillium, Inc a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.... Read More
